Miraculins Announces First Closing of Private Placement Offering

Miraculins Inc. (TSX VENTURE:MOM) (the "Company"), a medical diagnostic company
focused on acquiring, developing and commercializing diagnostic tests and risk
assessment technologies for unmet clinical needs, is pleased to announce the
first closing of a private placement offering (the "Offering") with aggregate
gross proceeds to the Company of $116,000 from the sale of 464,000 units
("Units") at a price of $0.25 per Unit. Each Unit is comprised of one common
share of the Company (a "Share") and one Share purchase warrant (a "Warrant").


Each Warrant entitles the holder to purchase one Share at a price of $0.35 per
Share for a period of 12 months from the date the Warrant is issued. The
Warrants are callable, at the option of the Company, at any time after four
months following their issuance, in the event that the closing price of the
Shares is at or above $0.50 per Share for any five out of 10 consecutive trading
days. The Shares and Warrants will be restricted from transfer for a period of
four months and a day from the date hereof in accordance with applicable
securities laws. Insiders of the Company participated by purchasing 40,000 Units
of the Offering. The net proceeds of the Offering will be used for general
operating, ongoing product development, inventory and sales and marketing
related costs.


The Company anticipates that a second closing will take place in the near term.

The closing of the Offering is subject to the final approval of the TSX Venture
Exchange.


About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and
commercializing non-invasive technologies for unmet clinical needs. A
significant number of promising diagnostic opportunities remain
un-commercialized because of the sizable gap between the discovery stage, when
research institutions are typically involved, and the commercialization stage,
when the larger commercial enterprises become interested. Miraculins has direct
experience in bridging this gap. The Company's Scout DS(R) system is the first
non- invasive diabetes testing system designed to provide a highly sensitive and
convenient method for measuring diabetes related biomarkers in the skin, the
accumulation of which are accelerated by abnormal blood sugar levels and
oxidative stress. Unlike current testing methods, a Scout DS(R) test requires no
blood draw, no fasting, and no waiting for a lab result. The product has been
used and validated in thousands of patients around the world. The Company's
PreVu(R) POC Test is a revolutionary new coronary artery disease risk assessment
technology that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. For more information visit
www.miraculins.com


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements include statements regarding the use of proceeds of the Offering and
the completion of a second closing of the private placement offering. These
forward-looking statements relate to, among other things, our objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and outlook,
including, without limitation, our anticipated future operating results, and
can, in some cases, be identified by the use of words such as "believe,"
"anticipate," "expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations, projections
or other characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward- looking statements, and actual
results may differ materially from those expressed or implied in such
statements. Important factors that could cause actual results to differ
materially from these expectations include, among other things: Miraculins'
early stage of development, lack of product revenues and history of operating
losses, uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Miraculins' filings with Canadian securities regulatory
authorities, as well as Miraculins' ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward- looking
statements may be found in the body of this news release. Miraculins cautions
that the foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking statements to make
decisions with respect to Miraculins investors and others should carefully
consider the foregoing factors and other uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Miraculins
cannot provide assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to update or
revise any forward-looking statement.


Scout DS(R) and PreVu(R) are registered trademarks of Miraculins Inc. All Rights
Reserved. 2014.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com
Miraculins Inc. (TSXV:MOM)
過去株価チャート
から 5 2024 まで 6 2024